K2 Therapeutics - About the company
K2 Therapeutics is a seed company. It operates as a Developer of cell therapies and medicines for solid tumor treatment. K2 Therapeutics has raised $50M in funding from MPM BioImpact. The company has 3395 active competitors, including 1130 funded and 783 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Company Details
Developer of cell therapies and medicines for solid tumor treatment. This biotechnology organization identifies and translates scientific assets into medical treatments. The development process utilizes a hub-and-spoke model to advance cell therapies and bispecific T-cell engagers. Focus remains on the clinical development of therapeutic programs intended to address specific medical conditions.
- Website
- k2tx.com
- Email ID
- *****@k2tx.com
Key Metrics
Stage
Seed
Total Funding
$50M in 1 round
Latest Funding Round
Investors
Ranked
2809th among 3395 active competitors
Sign up to download K2 Therapeutics' company profile
K2 Therapeutics's funding and investors
K2 Therapeutics has raised a total funding of $50M over 1 round. Its latest funding round was a Seed round on Aug 11, 2026 for $*****. 1 investor participated in its latest round. K2 Therapeutics has 1 institutional investor.
Here is the list of recent funding rounds of K2 Therapeutics:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Aug 11, 2026 | 5878713 | Seed | 9954216 | 1106296 | 1073114 | 6188720 |
Access funding benchmarks and valuations. Sign up today!View details of K2 Therapeutics's funding rounds and investors
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
K2 Therapeutics's Competitors and alternates
Top competitors of K2 Therapeutics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of K2 Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
5th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
9th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 72/100 | |
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
2809th |  K2 Therapeutics Seed | Developer of cell therapies and medicines for solid tumor treatment | $50M | 22/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on K2 Therapeutics's competitors? Click here to see the top ones
K2 Therapeutics's Investments and acquisitions
K2 Therapeutics has made no investments or acquisitions yet.
Reports related to K2 Therapeutics
Here is the latest report on K2 Therapeutics's sector:
News related to K2 Therapeutics
Media has covered K2 Therapeutics for a total of 2 events in the last 1 year, 1 of them has been about company updates and 1 about people movement.
•
Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCETncontentexchange•Aug 23, 2026•Antengene, K2 Therapeutics
•
K2 Therapeutics Appoints Dr. Ying Huang as Chief Executive Officer and Announces $50 Million Seed FinancingStock Screener•Aug 11, 2026•K2 Therapeutics
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about K2 Therapeutics
Explore our recently published companies
- Entrans - Prague based, 2003 founded, Funding Raised company
- Evolvez - New York based, 2019 founded, Unfunded company
- Kognico - New York based, 2003 founded, Unfunded company
- Happy Shark Media - New York based, 2019 founded, Unfunded company
- Spartan Institutional Research - New York based, 1996 founded, Unfunded company
- Ayoki Fabricon - Pune based, 1984 founded, Unfunded company
